title: Gene transfer and the treatment of haematological malignancy.
abstract: Gene therapy offers an additional therapeutic modality for treating haematological malignancy. Because gene therapies could be truly specific for the malignancy, they should ultimately prove both safe and effective. We have far to go before this full potential is realized, but gene transfer strategies are already showing therapeutic promise. Gene transfer may be used to correct the genetic defect in the tumour, to render it more susceptible to conventional therapies, or the normal host cells more resistant, to induce or amplify an antitumour immune response, or simply as a means of tracking the tumour or cells used for treatment. This article describes examples of each approach and discusses future prospects for the field.
authors: Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA.
authors: M K
authors: MK
authors: Brenner
mesh_terms: D000818:Animals; D000998:Antiviral Agents / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D019496:Cancer Vaccines; D020031:Epstein-Barr Virus Infections / Q000276:immunology; D015774:Ganciclovir / Q000627:therapeutic use; D018014:Gene Transfer Techniques; D015316:Genetic Therapy; D019337:Hematologic Neoplasms / Q000628:therapy*; D006412:Hematopoietic Stem Cells; D006689:Hodgkin Disease / Q000628:therapy / Q000821:virology; D006801:Humans; D007938:Leukemia / Q000628:therapy; D008232:Lymphoproliferative Disorders / Q000276:immunology / Q000821:virology; D011355:Prodrugs; D013602:T-Lymphocytes, Cytotoxic; D017735:Virus Latency
chemical_list: D000998:Antiviral Agents; D019496:Cancer Vaccines; D011355:Prodrugs; D015774:Ganciclovir